Intravitreal Bevacizumab Versus Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration: Findings from a Cochrane Systematic Review

Ophthalmology

Volumn 123, Issue 1, 2016, Pages 70-77.e1

  Solomon, Sharon D ^a   Lindsley, Kristina B ^b   Krzystolik, Magdalena G ^c   Vedula, Satyanarayana S ^d   Hawkins, Barbara S ^a,b,e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c Massachusetts Eye and Ear Infirmary   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR;

AGE RELATED MACULAR DEGENERATION; ARTICLE; FOLLOW UP; HUMAN; MEDLINE; OPHTHALMOLOGY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW; VISION; VISUAL ACUITY; VISUAL IMPAIRMENT; WORLD HEALTH ORGANIZATION; COMPLICATION; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINAL NEOVASCULARIZATION; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RANIBIZUMAB; RETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84951159951     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.09.002     Document Type: Article

References (26)

1. Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
3. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
4. Vedula SS, Krzystolik M. Antiangiogenic therapy with antivascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2008 Apr 16;(2):CD005139.
5. Solomon SD, Lindsley K, Vedula SS, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2014Aug 29;8:CD005139.
6. Higgins JPT, Green S, eds. Cochrane Handbook of Systematic Reviews of Interventions, Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at www. cochrane-handbook.org. Accessed December 31, 2013.
7. Krystolik MG, Woodcome HA, Reddy U. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for age-related macular degeneration. Cochrane Database Syst Rev 2008 Apr 16;(2):CD005139.
8. Review Manager (RevMan) [computer software]. Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2012.
9. NCT00559715. Prevention of vision loss in patients with agerelated macular degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab (VIBERA). Available at: Clinicaltrials. gov/show/NCT00559715. Accessed August 14, 2013.
10. NCT01127360. Lucentis compared to Avastin study [LUCAS]. A randomized, double blind, prospective multicenter study comparing the effect of Intravitreal injection of Bevacizumab (Avastin) to Ranibizumab (Lucentis) when give to patients with exudative (wet) age-related macular degeneration. Available at: Clinicaltrials.gov/show/NCT01127360. Accessed January 1, 2013.
11. NTR1704. Comparison of bevacizumab (Avastin) and ranibizumab (Lucentis) in exudative age-related macular degeneration. Available at: www.trialregister.nl/trialreg/admin/rctview. aspTC1704. Accessed May 17, 2013.
12. CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
13. Comparison of Age-related Macular Degeneration Treatments Trial (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98.
14. Subramanian ML, Abedi G, Ness S, et al. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye 2010;24:1708-15.
15. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411 [Erratum: Opthalmology 2012;119:1508].
16. Chakravarthy U, Harding SP, Rogers CA, et al; on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382:1258-67.
17. Krebs I, Schmetterer L, Boltz A, et al. A randomised doublemasked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 2013;97: 266-71.
18. Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL non-inferiority randomized trial. Ophthalmology 2013;120:2300-9.
19. Biswas P, Sengupa S, Choudhary R, et al. Comparative role of Intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. Indian J Ophthalmol 2011;59:191-6.
20. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108.
21. Dakin HA, Wordsworth S, Rogers CA, et al; on behalf of the IVAN Study Investigators. Cost-effectiveness of ranibizumab for age-related macular degeneration: 2-year findings from the IVAN randomized trial. BMJ Open 2014;4:3005094.
22. Moja L, Lucenteforte E, Kwag KH, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2014 Sep 15;9:CD011230.
23. Berg K, Pedersen TR, Sandvik L, Bragadottir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to the LUCAS treat-andextend protocol. Ophthalmology 2015;122:146-52.
24. Raftery J, Clegg A, Jones J, et al. Ranibizumab (Lucentis-) versus bevacizumab (Avastin-): modeling cost effectiveness. Br J Ophthalmol 2007;91:1244-6.
25. Stein JD, Newman-Casey PA,Mrinalini T, et al.Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. Ophthalmology 2014;121:936-45.
26. U.S. Department of Health and Human Services. Project number 5U10Ey023530e02: Follow-up study: Comparison of AMD Treatments Trial (CATT). Available at: http://projectreporter.nih.gov/projectinfodescription.cfmaid8732657&icde22041118&ddparam&ddvalue&ddsub5&csbdefault&csASC. Accessed June 15, 2015.